iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Dr. Reddy's Laboratories recalls 6 lots of one of its drugs

24 Apr 2024 , 03:46 PM

Dr. Reddy's Laboratories Ltd. has initiated a voluntary recall of six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg. The reason behind the recall is the presence of powder discoloration in some packets, which can lead to a decrease in potency. The issue was identified during an accelerated stability test and subsequent customer complaints.

There is a risk associated with reduced potency, particularly in patients with Phenylketonuria (PKU), as it can result in elevated Phenylalaninemia (Phe) levels. Elevated Phe levels pose a significant health risk, especially in infants and children, as they can lead to permanent neurocognitive deficits.

Potential consequences include irreversible intellectual disability, developmental delays, and seizures. Moreover, elevated Phe levels during pregnancy, especially in early stages, are linked with adverse outcomes such as microcephaly and congenital heart disease.

Despite the recall, Dr. Reddy’s Laboratories Inc. has not received any reports of adverse events associated with the affected product. The recalled product is primarily use for reducing blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-responsive PKU. It is packaged in individual packets, with each carton containing 30 packets.

Dr. Reddy’s Laboratories Inc. is actively communicating the recall to its distributors and customers through recall notification letters. They are facilitating the return of all recalled products to address the issue promptly. Those who possess the recalled product in their inventory are advised to inspect it immediately and quarantine any affected lots.

Consumers who have the recalled product should consult their physician before discontinuing its use to ensure proper management of their condition. Furthermore, consumers are urged to return the recalled product to the place of purchase for a refund or replacement.

If consumers have encountered any problems or adverse effects associated with the use of this drug product, they are encouraged to contact their healthcare provider for guidance and support.

This news hasn't affected the stock price majorly. At the time of writing stocks of DR. Reddy's were trading at ₹5949.60 which is a 0.42% dip than the previous close.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Business news
  • Dr Reddys Laboratories
sidebar mobile


Read More
Knowledge Centerplus

Logo IIFL Customer Care Number
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

Knowledge Centerplus

Follow us on


2024, IIFL Securities Ltd. All Rights Reserved

  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.